Javier Martin-Broto: Immunotherapy in combination in ESMO Sarcoma and Rare Cancers 2025
Javier Martin-Broto, Sarcoma Medical Oncologist at the Jiménez Díaz Foundation University Hospital, shared a post on LinkedIn:
“IMMUNOTHERAPY IN COMBINATION IN ESMO Sarcoma and Rare Cancers in Lugano, Switzerland. – Javier Martin-Broto
Mentioning immunotherapy and sarcomas in the same breath is indeed quite unusual. This is primarily because the vast majority of sarcomas don’t exhibit an immune-sensitive phenotype (typically low TMB, low PD-L1, and stable MSI).
However, I believe along with my team that immune checkpoint modulation in sarcomas hasn’t had its final say. Rather, it is just beginning to demonstrate its value. The combination of anthracycline-based chemotherapy with immune checkpoint inhibitors (ICI) is showing response rates of 60% and even higher.
This is unheard of in the context of advanced sarcomas. Although the maintenance phase remains the most vulnerable, and ICI alone isn’t sufficient, we are convinced that this is the path to improving the cure rate in the high-risk localized disease setting and enhancing first-line outcomes in advanced soft tissue sarcomas.
Targeting Immunogenic Cell Death seems a positive research avenue in sarcoma. It was a big pleasure to share the table with Sandra D’Angelo, Antoine Italiano, and Sandra Strauss.”
Read more about immunotherapy at OncoDaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023